

Appendix Table F44. Exploring clinical diversity in discontinuation rates due to adverse effects after duloxetine when compared to placebo

Reference	Country	Weeks of treatment	Age	Prior treatment	Concurrent medication	% Women	Inclusion of women with surgical risk factors for UI	Inclusion of those who failed prior treatments	Inclusion of minorities	Presence of mixed UI	Daily UI
Millard, 2004 ³⁵⁰	Poland, South Africa, Australia, Brazil, Argentina and Finland	12	53.7-52.6	Previous continence surgery including injections, 18.5% in active and 17.3% in control group	No response	100	No response	No response	Yes	No response	Yes
Cardozo, 2004 ²⁵¹	Australia, Canada, the Netherlands, and the United Kingdom	8	54.5-52.4	Prior continence surgery in 16.4% duloxetine and 14.8% placebo women	Hormone replacement therapy in 47.3% duloxetine and 40.7% placebo group	100	No response	No response	Yes	No response	Yes
Castro-Diaz, 2007 ²⁵⁴	64 study centers in 8 countries	8	52.7-53.3	No response	No response	100	No response	No response	No response	No response	Yes
Bent, 2008 ²³⁴	USA	8	53.2-54.2	Antimuscarinic agents (either tolterodine or oxybutynin) were used by 7.8% of subjects	Antidepressant medications, including other SNRIs and selective serotonin reuptake inhibitors: 19.4% in placebo and 23.0% in active group	100	No	No	Yes	Yes	Yes
Norton, 2002 ³⁵⁵	USA	12	49.3-53.2	No response	No response	100	No	No response	Yes	No response	Yes

Appendix Table F44. Exploring clinical diversity in discontinuation rates due to adverse effects after duloxetine when compared to placebo (continued)

Reference	Country	Weeks of treatment	Age	Prior treatment	Concurrent medication	% Women	Inclusion of women with surgical risk factors for UI	Inclusion of those who failed prior treatments	Inclusion of minorities	Presence of mixed UI	Daily UI
Lin, 2008 ³³⁹	Taiwan	8	53-56	Previous surgery had 3 women in duloxetine and 5 in placebo group	Were not permitted	100	No response	No response	No response	No response	Yes
Schagen van Leeuwen, 2008 ³⁷⁸	Germany, France, The Netherlands, Spain, Sweden, Switzerland and South-Africa	12	70.63-71.1	Previous incontinence surgery 15.3% in placebo and 11.9% in duloxetine	Approximately 80% of patients reported concomitant drug therapies before and after randomization. Behavioral therapy 0.8% in placebo and 0.7% in duloxetine; Current PFMT 9.9% in placebo and 9.7% in duloxetine group	100	No	No response	Yes	Yes	Yes
Dmochowski, 2003 ²⁷⁹	Canada and the United States	12	52.3-53.3	% prior continence surgery, including injection 12.2% in duloxetine and 13.1% in placebo group % PFMT 16.9% in duloxetine and 18.0% in placebo group	No response	100	No response	No response	Yes	No response	Yes

Appendix Table F44. Exploring clinical diversity in discontinuation rates due to adverse effects after duloxetine when compared to placebo (continued)

Reference	Country	Weeks of treatment	Age	Prior treatment	Concurrent medication	% Women	Inclusion of women with surgical risk factors for UI	Inclusion of those who failed prior treatments	Inclusion of minorities	Presence of mixed UI	Daily UI
van Kerrebroeck, 2004 ³⁹³	Belgium, Canada, Denmark, France, Germany, The Netherlands, Sweden and the United Kingdom	12	52-54	Prior continence surgery in 7.7% in duloxetine and in 7.7% placebo group	No response	100	No response	No response	Yes	No response	Yes